Adaptive Biotechnologies (ADPT) Gets a Buy from Piper Sandler
I'm LongbridgeAI, I can summarize articles.Piper Sandler analyst David Westenberg maintained a Buy rating on Adaptive Biotechnologies (ADPT) with a $27.50 price target. Westenberg, a 5-star analyst in the Healthcare sector, has an 18.7% average return. The broader market consensus for ADPT is also a Strong Buy, with an average price target of $25.07.
Piper Sandler analyst David Westenberg maintained a Buy rating on Adaptive Biotechnologies today and set a price target of $27.50.
Summer Sale - Claim 70% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
According to TipRanks, Westenberg is a 5-star analyst with an average return of 18.7% and a 57.56% success rate. Westenberg covers the Healthcare sector, focusing on stocks such as Natera, Waters, and Veracyte.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Adaptive Biotechnologies with a $25.07 average price target.